Home Healthcare Biotechnology Biosimilar Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others), By Indication (Oncology, Autoimmune diseases, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Biosimilar Monoclonal Antibodies Market Size Analysis
    1. Introduction
    2. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
      1. Adalimumab
      2. Bevacizumab
      3. Infliximab
      4. Rituximab
      5. Trastuzumab
      6. Others
    3. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
      1. Oncology
      2. Autoimmune diseases
      3. Others
    4. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Others
  7. North America Biosimilar Monoclonal Antibodies Market Size Analysis
    1. Introduction
    2. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
      1. Adalimumab
      2. Bevacizumab
      3. Infliximab
      4. Rituximab
      5. Trastuzumab
      6. Others
    3. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
      1. Oncology
      2. Autoimmune diseases
      3. Others
    4. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Others
    5. U.S.
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    6. Canada
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
  8. Europe Biosimilar Monoclonal Antibodies Market Size Analysis
    1. Introduction
    2. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
      1. Adalimumab
      2. Bevacizumab
      3. Infliximab
      4. Rituximab
      5. Trastuzumab
      6. Others
    3. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
      1. Oncology
      2. Autoimmune diseases
      3. Others
    4. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Others
    5. U.K.
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    6. Germany
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    7. France
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    8. Spain
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    9. Italy
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    10. Russia
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    11. Nordic
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    12. Benelux
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    13. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
  9. APAC Biosimilar Monoclonal Antibodies Market Size Analysis
    1. Introduction
    2. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
      1. Adalimumab
      2. Bevacizumab
      3. Infliximab
      4. Rituximab
      5. Trastuzumab
      6. Others
    3. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
      1. Oncology
      2. Autoimmune diseases
      3. Others
    4. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Others
    5. China
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    8. India
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    10. Taiwan
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    11. South East Asia
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    12. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
  10. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Analysis
    1. Introduction
    2. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
      1. Adalimumab
      2. Bevacizumab
      3. Infliximab
      4. Rituximab
      5. Trastuzumab
      6. Others
    3. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
      1. Oncology
      2. Autoimmune diseases
      3. Others
    4. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Others
    5. UAE
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    6. Turkey
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    7. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    8. South Africa
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    9. Egypt
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    10. Nigeria
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    11. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
  11. LATAM Biosimilar Monoclonal Antibodies Market Size Analysis
    1. Introduction
    2. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
      1. Adalimumab
      2. Bevacizumab
      3. Infliximab
      4. Rituximab
      5. Trastuzumab
      6. Others
    3. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
      1. Oncology
      2. Autoimmune diseases
      3. Others
    4. Biosimilar Monoclonal Antibodies Market Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Others
    5. Brazil
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    6. Mexico
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    7. Argentina
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    8. Chile
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    9. Colombia
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
    10. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      3. Market Size & Forecast By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      4. Market Size & Forecast By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
  12. Competitive Landscape
    1. Biosimilar Monoclonal Antibodies Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Roche Holding AG
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Novartis AG
    3. Pfizer Inc.
    4. Samsung Bioepis
    5. Amgen Inc.
    6. Viatris Inc.
    7. Teva Pharmaceutical Industries Ltd.
    8. Biogen Inc.
    9. Celltrion, Inc.
    10. Fresenius Kabi AG
    11. Sandoz AG
    12. Boehringer Ingelheim International GmbH
    13. Merck KGaA
    14. Amneal Pharmaceuticals, Inc.
    15. Biocon Limited
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.